Zermatt Resort & Spa - Utah Floorplan

Registered Attendees


Registered attendees (and speakers, organizers, etc.) will have access to the following items from their Account page:

  • Abstracts from speakers and poster sessions, including the joint meeting abstracts, available 30 days prior to the meeting (You can edit your own abstract from My Account page as well)

    NOTE: Abstract authors/submitters may choose to not have their abstract available online and in the secure mobile app until a week before the meeting.

  • Full participant list, including joint meeting participants
  • Printable Invoices and Invitation Letters
  • Scholarship Information
  • Lodging Information

Login to My Account page

This meeting took place in 2010



For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.

Advances in Biopharmaceuticals (A2)


Organizer(s) John M. McPherson and Thomas F. Bumol
January 8—13, 2010
Zermatt Resort & Spa - Utah • Midway, Utah USA
Abstract Deadline: Sep 14, 2009
Late Abstract Deadline: Oct 5, 2009
Scholarship Deadline: Sep 14, 2009
Early Registration Deadline: Nov 5, 2009

Sponsored by Alnylam Pharmaceuticals, Inc. and Pfizer Global Research & Development

Summary of Meeting:
This meeting will contain eight sessions covering both biotechnology discovery platforms supporting biopharmaceutical product research and development (4 sessions) and specific disease areas where biopharmaceuticals either have or are likely to have a major positive impact on clinical outcomes for patients (4 sessions).

View Scholarships/Awards
No registration fees are used to fund entertainment or alcohol at this conference

Conference Program    Print  |   View meeting in 12 hr (am/pm) time


FRIDAY, JANUARY 8

15:00—19:30
Registration

Matterhorn Foyer
18:30—19:30
Refreshments

Matterhorn Foyer
19:30—20:30
Keynote Address
Meeting has ended...abstracts no longer viewable online.

Matterhorn Ballroom
Napoleone Ferrara, University of California, San Diego, USA
The Avastin Story: Challenges and Lessons


SATURDAY, JANUARY 9

07:00—08:00
Breakfast

Schneitter's
08:00—11:00
Antibody Discovery and Engineering
Meeting has ended...abstracts no longer viewable online.

Matterhorn Ballroom
Matthew Sleeman, MedImmune, USA
Antibody Structure Function Relationships

Tillman U. Gerngross, Adimab, Inc., USA
Adimab’s Novel Human Antibody Discovery Platform: A New Benchmark for Antibody Discovery Technologies

John R. Desjarlais, Xencor, USA
Creating Novel and Enhanced Antibody Therapeutics through Fc Engineering

James A. Van Deventer, California Institute of Technology, USA
Short Talk: Antibody Fragment Engineering With Non-Canonical Amino Acids

11:00
On Own for Lunch and Recreation

09:20—09:40
Coffee Break

Matterhorn Foyer
16:30—17:00
Coffee Available

Matterhorn Foyer
17:00—19:00
Protein and Peptide Engineering
Meeting has ended...abstracts no longer viewable online.

Matterhorn Ballroom
W. David Shen, Merck & Co., Inc., USA
From Mammalian Cell Display to Cross-Species Display of Antibodies

Clark Pan, Genzyme Corporation, USA
Carbohydrate Engineering of Acid alpha-Glucosidase for Treatment of Pompe Disease

David V. Liu, Massachusetts Institute of Technology, USA
Short Talk: Engineered Interleukin-2 Antagonists for the Inhibition of Regulatory T Cells

19:00—20:00
Social Hour with Lite Bites

Grindelwald/Davos

SUNDAY, JANUARY 10

07:00—08:00
Breakfast

Schneitter's
08:00—11:00
Next Generation Protein-Based Biopharmaceuticals
Meeting has ended...abstracts no longer viewable online.

Matterhorn Ballroom
Volker Schellenberger, Amunix Inc., USA
Protein Pharmaceuticals Comprising an XTEN Half-Life Extension Module

Richard J.M. Ross, University of Sheffield, UK
Hormone/Hormone Receptor Fusion Proteins for Improving the Pharmacokinetic/Pharmacodynamic Properties of Hormone Replacement Therapies

Peter D. Senter, Seattle Genetics Inc., USA
Antibody-Drug Conjugates for Cancer Therapy

Chengbin Wu, Abbott Bioresearch Center, USA
Protein Engineering of DVD-Ig: Focusing on Pharmacokinetics, Manufacturing, and Preformulation Studies

Bernd J. Wranik, Genentech, USA
Short Talk: LUZ-Y: An Engineered Antibody Format for the Production of One-Armed and Bispecific Antibodies in Mammalian (CHO) Cells

09:20—09:40
Coffee Break

Matterhorn Foyer
11:00—13:00
Poster Setup

Grindelwald/Davos
11:00
On Own for Lunch and Recreation

13:00—22:00
Poster Viewing

Grindelwald/Davos
16:30—17:00
Coffee Available

Matterhorn Foyer
17:00—19:00
Nucleic Acid-Based Biopharmaceuticals
Meeting has ended...abstracts no longer viewable online.

Matterhorn Ballroom
James M. Wilson, University of Pennsylvania, USA
Gene Therapy: Lessons Learned and Opportunities for the Future

C. Frank Bennett, Ionis Pharmaceuticals, Inc., USA
Progress in Antisense Therapeutics

Dinah Sah, Voyager Therapeutics, USA
Development of RNAi Therapeutics

Pengbo Zhou, Weill Cornell Medical College, USA
Short Talk: Integration of RNAi and Protein Knockout Technology for Efficient Eradication of Cellular Proteins

19:00—20:00
Social Hour with Lite Bites

Grindelwald/Davos
19:30—22:00
Poster Session 1

Grindelwald/Davos

MONDAY, JANUARY 11

07:00—08:00
Breakfast

Schneitter's
08:00—11:00
Cancer and Cancer Supportive Care
Meeting has ended...abstracts no longer viewable online.

Matterhorn Ballroom
Michael Reiss, Robert Wood Johnson Medical School, USA
TGF-beta as a New Cancer Therapy Target

Elisabeth G.E. de Vries, Universitair Medisch Centrum Groningen, Netherlands
Use of Zirconium-89 Labeled Antibodies for Tumor Imaging: Possible Applications for Guiding Targeted Tumor Therapy

Patrick A. Baeuerle, Amgen Research (Munich) GmbH, Germany
Cancer Therapy by T Cell-Engaging BiTE Antibodies

Antonio Gualberto, Pfizer Oncology, USA
Development of Figitumumab (CP-751,871), a Fully Human Monoclonal Antibody against the IGF-1R

John C. Zwaagstra, Biotechnology Research Institute NRCC, Canada
Short Talk: Design and Efficacy of Single-Chain Traps Targeting Ligands of the Transforming Growth Factor-beta (TGF-beta) Family: The New Generation of Cancer Therapeutics/Diagnostics

09:20—09:40
Coffee Break

Matterhorn Foyer
11:00
On Own for Lunch and Recreation

13:00—22:00
Poster Viewing

Grindelwald/Davos
16:30—17:00
Coffee Available

Matterhorn Foyer
17:00—19:00
Immune-Mediated Diseases/Transplant
Meeting has ended...abstracts no longer viewable online.

Matterhorn Ballroom
C. Randal Mills, California Institute for Regenerative Medicine, USA
Mesenchymal Stem Cells for Treatment of GVHD

Alasdair Coles, University of Cambridge, UK
Anti-CD52 Antibodies for the Treatment of Multiple Sclerosis

Kristine Kikly, Eli Lilly and Company, USA
Anti-BAFF for the Treatment of Rheumatoid Arthritis

19:00—20:00
Social Hour with Lite Bites

Grindelwald/Davos
19:30—22:00
Poster Session Viewing

Grindelwald/Davos

TUESDAY, JANUARY 12

07:00—08:00
Breakfast

Schneitter's
08:00—11:00
Diabetes
Meeting has ended...abstracts no longer viewable online.

Matterhorn Ballroom
Bart Keymeulen, Vrije Universiteit Brussel, Belgium
Preservation of Beta Cell Function in Human Type 1 Diabetes

Sushil G. Rane, NIDDK, National Institutes of Health, USA
Protection from Obesity and Diabetes by Blockade of TGF-beta/Smad3 Signaling

Alexei Kharitonenkov, Novo Nordisk, USA
FGF-21 and its Novel Variants to Treat Metabolic Disorders

Lucienne Chatenoud, INSERM U1151, Hôpital Necker-Enfants Malades, France
Restoration of Self Tolerance in Autoimmune Diabetes

Biju Parekkadan, Rutgers University, USA
Short Talk: Natural Therapeutics Derived from the Bone Marrow Stroma

09:20—09:40
Coffee Break

Matterhorn Foyer
11:00
On Own for Lunch and Recreation

16:30—17:00
Coffee Available

Matterhorn Foyer
17:00—19:00
Metabolic and Neurological Disorders
Meeting has ended...abstracts no longer viewable online.

Matterhorn Ballroom
Ronald B. DeMattos, Lilly Research Laboratories, USA
Abeta Immunotherapy: The Development of Compound Specific Biomarkers to Aid the Translation of Preclinical to Clinical Studies

Mike Ominsky, Amgen Inc., USA
OPG/RANKL and Sclerostin; Physiological Regulators of Bone Density; Targets for the Treatment of Bone Loss Indications

Marco A. Passini, Genzyme Corporation, USA
Gene and Antisense Oligonucleotide Therapies for Spinal Muscular Atrophy

John Chaddock, Syntaxin Ltd, UK
Short Talk: Clostridial Endopeptidases - A Novel Platform for Therapeutic Proteins

19:00—20:00
Social Hour with Lite Bites

Grindelwald/Davos
20:00—23:00
Entertainment

Grindelwald/Davos

WEDNESDAY, JANUARY 13

 
Departure


*Session Chair †Invited, not yet responded.



We gratefully acknowledge support for this conference from:


Directors' Fund


These generous unrestricted gifts allow our Directors to schedule meetings in a wide variety of important areas, many of which are in the early stages of research.

Click here to view all of the donors who support the Directors' Fund.



We gratefully acknowledge additional support for this conference from:

Alnylam Pharmaceuticals, Inc. BioMarin Pharmaceutical Inc.
Dendreon Corporation Myriad-RBM
Otsuka America Pharmaceutical, Inc. Pfizer Global Research & Development

We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:



Amunix Inc.


Educational donation provided by Amgen


Educational grant from Lilly USA, LLC


Genzyme Corporation


Isis Pharmaceuticals, Inc.


MedImmune


Merck Vaccine Division


Pfizer Inc.


Regeneron Pharmaceuticals, Inc.


Seattle Genetics, Inc.


We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:

ACS Publications

Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:


Click here to view more of these organizations


If your organization is interested in joining these entities in support of Keystone Symposia, please contact: Sarah Lavicka, Director of Development, Email: sarahl@keystonesymposia.org,
Phone:+1 970-262-2690

Click here for more information on Industry Support and Recognition Opportunities.

If you are interested in becoming an advertising/marketing in-kind partner, please contact:
Yvonne Psaila, Director, Marketing and Communications, Email: yvonnep@keystonesymposia.org,
Phone:+1 970-262-2676